title: Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis.
abstract: OBJECTIVE
  To compare effectiveness, associated cost of outcomes and cost-effectiveness of a single annual infusion of zoledronic acid versus current treatment strategies plans for postmenopausal osteoporosis in France.
  
  
  METHODS
  Twelve simulation-based models were built to investigate three types of fractures: vertebral (VF), non-vertebral excluding hip (NVF) and hip (HF), comparing two groups: zoledronic acid and current postmenopausal antiosteoporotic treatment strategies. Two effectiveness comparability assumptions have been tested: specific agent efficacy values, and same standard efficacy values for all active agents. Direct medical costs included drug costs, medical visits, monitoring and fracture management. Adherence levels were integrated into the model under the assumption that non-adherent patients had treatment effects similar to the levels of placebo effectiveness.
  
  
  RESULTS
  Using the most conservative assumption (same standard efficacy values for all active agents), zoledronic acid strategy results in less vertebral, non-vertebral and hip fractures than other current antiosteoporotic treatment options over 3 years: 12.04% vs. 14.18%, 10.61% vs. 11.28% and 2.82% vs. 4.64% respectively, (p<0.001). In addition, zoledronic acid is more cost-effective than the current treatment strategies in all types of fractures (p<0.001): 1497 euros vs. 1685 euros per VF avoided, 1337 euros vs. 1404 euros per NVF avoided and 1216 euros vs. 1323 euros per HF avoided.
  
  
  CONCLUSIONS
  Zoledronic acid is a cost-effective treatment strategy regardless of fracture type or effectiveness comparability assumptions.
authors.affiliation: Inserm ERI 12, service de rhumatologie, CHU d'Amiens, 1, place Victor-Pauchet, 80054 Amiens, France. fardellone.patrice@chu-amiens.fr
authors.forename: Patrice
authors.initials: P
authors.lastname: Fardellone
authors.forename: Bernard
authors.initials: B
authors.lastname: Cortet
authors.forename: Erick
authors.initials: E
authors.lastname: Legrand
authors.forename: Xavier
authors.initials: X
authors.lastname: Bresse
authors.forename: Ségolène
authors.initials: S
authors.lastname: Bisot-Locard
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Vigneron
authors.forename: Ariel
authors.initials: A
authors.lastname: Beresniak
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004164:Diphosphonates / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005598:Fractures, Spontaneous / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D017059:Models, Econometric; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D005791:Patient Care / Q000191:economics*; D016032:Randomized Controlled Trials as Topic; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid